Chemotherapy of advanced endometrial carcinoma

Stanojevic, Zorica; Todorovska, Ilinka; Djordjević, Biljana; Lilic, Vekoslav; Zivanovic, Danijela

doi:10.2298/vsp0708555s

Cited by 2 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-endometrioid adenocarcinoma is primarily noted in postmenopausal women; does not relate to estrogen, tamoxifen, or other stimuli; and its prognosis is poor. [3] The treatment of EC depends upon the surgical pathologic stage and high-risk factors of recurrence that enable an appropriate surgical plan and auxiliary measures to be chosen.…”

Section: Introductionmentioning

confidence: 99%

Significance of differential expression of OLFM4 in the development of endometrial adenocarcinoma

Huang

Liu

et al. 2022

Medicine

View full text Add to dashboard Cite

The incidence of endometrial adenocarcinoma (EA) has increased worldwide in recent years due to the widespread use of estrogen therapy and the overall increase in life expectancy. However, we know of no sensitive molecular index that can be used to predict the onset of EA, evaluate the therapeutic effects of treatment agents, or provide prognostic benefit in post-treatment follow-up. To explore the correlation between human olfactomedin 4 (OLFM4) and the clinicopathologic parameters of EA, and to determine the precise involvement of OLFM4 as a related factor in the occurrence and development of EA. We enrolled 61 gynecologic patients for a retrospective study at the Tai'an Central Hospital of Shandong Province from January 1, 2016, to June 30, 2022. We determined the expression levels of estrogen receptor α (ERα), progesterone receptor (PR), and OLFM4 proteins in endometrial tissue with the immunohistochemical S-P staining method, and analyzed the correlations among ERα, PR, and OLFM4 protein expression levels and with the pathologic stage, histologic grade, myometrial invasiveness, and lymphatic metastasis of EA. The expression levels of OLFM4 in EA were higher than in normal endometrium (P = .036). The expression level of OLFM4 protein in stage II-III patients was higher than that in stage I patients (P = .034), and the expression levels of ERα and PR proteins in EA were lower than those in normal endometrial tissue (P = .014 and P = .0005). While we observed no correlation in endometrial tissues of disparate pathologic types between OLFM4 and the expression levels of ERα and PR proteins, we noted a positive correlation between the expression levels of ERα and PR protein. The expression level of OLFM4 protein increased with the malignant degree of endometrial lesions and OLFM4 protein expression was related to the FIGO stage of EA. And OLFM4 protein can be used as 1 of the potential diagnostic factors for endometrial lesions, which is worthy of further study.

show abstract

Section: Introductionmentioning

confidence: 99%

Significance of differential expression of OLFM4 in the development of endometrial adenocarcinoma

Huang

Liu

et al. 2022

Medicine

View full text Add to dashboard Cite

show abstract

Gynecologic oncology surgical procedures in the General hospital ”dr. Radivoj Simonovic” in Sombor in the period from 2011-2021

Djurdjevic¹,

Racic²,

Zakula³

2022

Med pregl

View full text Add to dashboard Cite

Introduction. In the period from 2011 - 2021, 1482 gynecologic surgeries were performed at the Department of Gynecology and Obstetrics of the General Hospital in Sombor, of which 50 (3.4%) were gynecologic oncology surgical procedures. The distribution of the malignant tumor localization was as follows: vulva 4 (8%), cervix 13 (26%), endometrium 24 (48%), and ovary 9 (18%). Material and Methods. The preoperative diagnosis of all patients included standard laboratory tests of blood and urine, chest X-ray, internal medicine specialist examination, electrocardiography, and imaging procedures (magnetic resonance imaging or computed tomography) of the small pelvis and abdomen. In all cases, the diagnosis of vulvar, cervical, and endometrial cancer was made preoperatively, based on pathohistological findings of the biopsy samples of tumor tissue or material obtained using exploratory curettage. In ovarian cancer, the diagnosis was made during surgery based on ex tempore pathohistological analysis. Results. Most of the operated patients were in the International Federation of Gynecology and Obstetrics stage I - 39 (78%) and the most common pathohistological type of tumor was adenocarcinoma of different localizations - 29 (58%). The number of lymph nodes removed per surgery was 16 - 39 (x: 19) and lymphovascular invasion was present in 31 (62%) operated patients. Intraoperative complications (bleeding, ureteral injury, infection, and wound dehiscence) occurred in 8 (16%) patients, recurrence occurred in 3 (6%), and postoperative lethal outcome occurred in 4 (8%) patients. Conclusion. The essential condition for performing gynecologic oncology surgical procedures in a secondary level healthcare facility is a well-trained gynecology surgeon who has received complete training in gynecologic oncology at the tertiary level, as well as the optimal number of gynecologic oncology surgeries in accordance with recommendations of the European Society of Gynecological Oncology.

show abstract

Chemotherapy of advanced endometrial carcinoma

Cited by 2 publications

References 39 publications

Significance of differential expression of OLFM4 in the development of endometrial adenocarcinoma

Significance of differential expression of OLFM4 in the development of endometrial adenocarcinoma

Gynecologic oncology surgical procedures in the General hospital ”dr. Radivoj Simonovic” in Sombor in the period from 2011-2021

Contact Info

Product

Resources

About